about
Interplay between scatter factor receptors and B plexins controls invasive growthAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerThe semaphorin 4D receptor controls invasive growth by coupling with MetSema4D induces angiogenesis through Met recruitment by Plexin B1Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth.p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling.Cancer therapy: can the challenge be MET?Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages.ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.How Can Gastric Cancer Molecular Profiling Guide Future Therapies?Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.Only a subset of Met-activated pathways are required to sustain oncogene addiction.MicroRNAs impair MET-mediated invasive growth.Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling.MET overexpression turns human primary osteoblasts into osteosarcomas.HGF/MET signalling protects Plasmodium-infected host cells from apoptosis.Targeted therapies for gastric cancer: failures and hopes from clinical trialsYAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.Hepatocyte growth factor and its receptor are required for malaria infection.Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts.Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene AddictionSilencing the MET oncogene leads to regression of experimental tumors and metastasesEnhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signalingPro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS)The landscape of d16HER2 splice variant expression across HER2-positive cancersTargeted therapies in cancer and mechanisms of resistanceA Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI TraitsIncreased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted TherapiesPatient-Derived Orthotopic Xenograft models in gastric cancer: a systematic review
P50
Q24295561-0DF54979-C04F-4E22-817B-4BB7965F1F44Q24563539-D2D47B26-7CBC-4BFE-8B21-BAF739ABBA3FQ28219215-54035FB2-7C3B-48CA-BD71-E061CD71D53BQ28301113-298D82A3-1957-43EC-9FDC-49055A22CCB5Q33942266-03E4AAE6-72BC-4B1D-A375-11A8B5D9FB90Q34386024-2407397B-2031-4D0A-ABEF-3EBBF925920DQ34454518-3C09950C-ECDA-4539-A399-036FF9078EFEQ36159458-A7B6C75E-3832-4758-B245-454A2186418AQ36742291-54C4705F-9C7A-4A3C-9582-0C289DB95CB9Q37355020-0A70C39F-1183-4D38-A85C-B1A5E9248587Q38751892-F2408B14-8752-4AEB-A978-4C74D42D439CQ38853530-EBCCFC4F-CABB-43D7-961D-FA87FB289D1BQ38976616-5B70DE08-718F-4E70-9D8C-9493837E797FQ39655921-F7C474FD-4D2D-412A-A09B-48987D17C43DQ39758066-88D3020D-3532-40D0-AE0A-8143B09133E5Q39906019-83F125F9-34D4-4714-98D9-2B6FE0B414D8Q40135901-10E2DC96-58FC-4F3D-9155-779053CE02A2Q40285015-103FC994-A8C9-43EE-85CB-0C4A35A9B059Q40448134-3D5FFEA2-5F77-4210-8BFE-B5E04F13EBB1Q41340207-A080A4A7-4160-444C-BD80-700A8E7197D0Q43632068-97759465-9B87-4BC5-A354-AD87DC120749Q47968668-94ABF2AE-6F61-4B93-8315-BA3D297F9D9CQ50058854-5A91CFAD-BCF3-494B-BA6E-C121E71307AFQ51019075-401B4A35-749D-4D25-AFBE-6A7E445141D6Q52638232-C04318F1-8F22-4856-886E-A405F74B5F88Q58164795-AD81892E-537E-4074-BA4A-9E7E583D9BE9Q58164852-0BE4B8B6-46EB-4A41-A952-8C419FE313BFQ58379681-3CF19B78-D1BB-4476-8FFD-F390F939CCC8Q62030472-F524C76F-3C18-43EB-8055-1F56A6888D56Q64065309-0486C2C5-A6B7-4B61-AD08-F9C62A47EB10Q88008645-89B348C0-6092-44B1-A5D0-4664ACADB912Q90493756-6AABF6FE-4A65-44D2-B9AC-11D86DB24A21Q91264742-2DCC6835-5039-432E-823A-F77E4FEEAC2CQ91614746-37E68DFB-FF39-4BC2-B6A1-84ABCA5FAF4C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Simona Corso
@ast
Simona Corso
@en
Simona Corso
@es
Simona Corso
@nl
type
label
Simona Corso
@ast
Simona Corso
@en
Simona Corso
@es
Simona Corso
@nl
prefLabel
Simona Corso
@ast
Simona Corso
@en
Simona Corso
@es
Simona Corso
@nl
P106
P1153
7004136805
P21
P31
P496
0000-0002-5069-1503